Illumina to Buy Avantome for Up to $60M; Long, Cheap Reads Will Target Sanger | GenomeWeb
Illumina said last week that it plans to acquire Avantome, a privately held company that is developing a low-cost, long-read sequencing technology, for $25 million in up-front cash and up to $35 million in contingent payments.
During the firm’s second-quarter conference call, Illumina President and CEO Jay Flatley said that Avantome’s technology, as a product, will have applications in both the research and diagnostic markets and will be complementary to Illumina’s Genome Analyzer. 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Determining who is and is not an author and where a researcher should fall on a list of authors can be a tricky task, Nature News writes.

In PNAS this week: variant protective against Alzheimer's disease, effect of whole-genome duplication on methylation in rice, and more.

Genome editing is also bringing up questions when applied to farm animals, the New York Times reports.

Through a transcriptome study, researchers home in on the activity of inflammation-linked genes in chronically lonely people.